RECOVERY is an international clinical trial identifying treatments that may be beneficial for people hospitalised with pneumonia.
RECOVERY started in the UK in early 2020 as the Randomised Evaluation of COVID-19 Therapy, a clinical trial testing treatments for people admitted to hospital with COVID-19 pneumonia. Since then it has identified five life-saving treatments for COVID-19, and shown that several other commonly used treatments were not effective.
RECOVERY is now open at sites across Europe, Asia and Africa and in 2023 expanded to test treatments of other types of pneumonia including influenza and non-viral community-acquired pneumonia.
trial registrations
The RECOVERY Trial is registered at ISRCTN50189673
EU Clinical Trials Register: EudraCT 2020-001113-21
Clinical Trials.gov: NCT04381936
A range of promising but unproven treatments are being evaluated in RECOVERY. The treatments being tested depend on the cause of pneumonia:
For patients with pneumonia caused by influenza
- oseltamivir (an antiviral treatment)
- baloxavir (an antiviral treatment)
- corticosteroids
For patients with pneumonia caused by other organisms (often referred to as 'community-acquired pneumonia' or CAP)
- corticosteroids
Data from the trial are regularly reviewed so that any effective treatment can be identified quickly and made available to all patients. Please see our news page for results that RECOVERY has found. The RECOVERY Trial team constantly review information on new drugs and may include promising ones in the trial in future.
FUNDERS
This trial is supported by grants to the University of Oxford from the National Institute for Health and Care Research (NIHR), UK Research and Innovation, Wellcome, and Flu Lab and by core funding provided by the Bill and Melinda Gates Foundation, the Foreign, Commonwealth & Development Office, Health Data Research UK, the NIHR Oxford Biomedical Research Centre, NIHR Clinical Trials Unit Support Funding, and Wellcome.